Next Article in Journal
Comparison of Liver Detargeting Strategies for Systemic Therapy with Oncolytic Adenovirus Serotype 5
Next Article in Special Issue
Aptamer Cell-Based Selection: Overview and Advances
Previous Article in Journal
Plant Virus Expression Vectors: A Powerhouse for Global Health
Previous Article in Special Issue
Development of Phosphorothioate DNA and DNA Thioaptamers
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview
Biomedicines 2017, 5(3), 45;

Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects

Internal Medicine, University of Iowa, Iowa City, IA 52242, USA
Molecular & Cellular Biology Program, Holden Comprehensive Cancer Center, Radiation Oncology, Abboud Cardiovascular Research Center, and Environmental Health Sciences Research Center (EHSRC), University of Iowa, Iowa City, IA 52242, USA
Author to whom correspondence should be addressed.
Received: 2 July 2017 / Revised: 2 August 2017 / Accepted: 3 August 2017 / Published: 9 August 2017
(This article belongs to the Special Issue Engineering Aptamers for Biomedical Applications)
Full-Text   |   PDF [2437 KB, uploaded 9 August 2017]   |  


Synthetic nucleic acid ligands (aptamers) have emerged as effective delivery tools for many therapeutic oligonucleotide-based drugs, including small interfering RNAs (siRNAs). In this review, we summarize recent progress in the aptamer selection technology that has made possible the identification of cell-specific, cell-internalizing aptamers for the cell-targeted delivery of therapeutic oligonucleotides. In addition, we review the original, proof-of-concept aptamer-siRNA delivery studies and discuss recent advances in aptamer-siRNA conjugate designs for applications ranging from cancer therapy to the development of targeted antivirals. Challenges and prospects of aptamer-targeted siRNA drugs for clinical development are further highlighted. View Full-Text
Keywords: aptamers; RNA interference; targeted therapy aptamers; RNA interference; targeted therapy

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Kruspe, S.; Giangrande, P.H. Aptamer-siRNA Chimeras: Discovery, Progress, and Future Prospects. Biomedicines 2017, 5, 45.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Biomedicines EISSN 2227-9059 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top